Richard Martin - Concepedia

Author

Richard Martin

Exelixis (United States)

Also Known As

Richard Martin

Publications

884

Citations

H-Index

Concepts

All Affiliations

Exelixis (United States)Bristol-Myers Squibb (United States)Rutgers, The State University of New Jersey Xalud Therapeutics (United States)

About

Richard Martin is an author at Exelixis (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	595
2	Biochemistry	2	2	202
3	Engineering	1	1	44
4	Natural Sciences	1	1	161
5	Biomedical Engineering	1	1	44

Richard Martin

Publications

857

Citations

H-Index

Page 1

	Year	Citations
Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand Patricia J. Willy, Ian Murray, Jing Qian, Proceedings of the National Academy of Sciences	2004	191
Identification of a Selective Inverse Agonist for the Orphan Nuclear Receptor Estrogen-Related Receptor α Brett B. Busch, William C. Stevens, Richard Martin, Journal of Medicinal Chemistry Molecular PharmacologyEstrogen-related Receptor AlphaSignal TransductionEndocrine MechanismMedicine	2004	166
Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR) Brenton Flatt, Richard Martin, Tielin Wang, Journal of Medicinal Chemistry Chronic AdministrationMolecular BiologyFarnesoid X ReceptorPharmacotherapyVivo Optimization	2009	161
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils Todd G. Kirchgessner, Paul G. Sleph, Jacek Ostrowski, Cell Metabolism InflammationMetabolic SyndromeCirculating NeutrophilsOxysterolHuman Lipid	2016	155
Transdermal and transbuccal drug delivery systems: Enhancement using iontophoretic and chemical approaches Longsheng Hu, Sérgio M.C. Silva, Bassam B. Damaj, International Journal of Pharmaceutics NanomedicineEngineeringMedicinePharmaceutical TechnologyChemical Approaches	2011	44
Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ Ellen K. Kick, Richard Martin, Yinong Xie, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyDrug TargetBiochemistryMedicineMechanism Of Action	2014	41
Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates Todd G. Kirchgessner, Richard Martin, Paul G. Sleph, Journal of Pharmacology and Experimental Therapeutics	2014	39
Discovery of Highly Potent Liver X Receptor β Agonists Ellen K. Kick, Brett B. Busch, Richard Martin, ACS Medicinal Chemistry Letters	2016	32
Enhanced in vitro transbuccal drug delivery of ondansetron HCl Longsheng Hu, Bassam B. Damaj, Richard Martin, International Journal of Pharmaceutics Pharmaceutical ScienceMedicinePharmacotherapyOndansetron HclPharmacology	2010	28

Page 1